Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.68 |
| ▸ | RAB9A | P51151 | 9/20 | 0.68 |
| ▸ | SCD | O00767 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.56 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.56 |
| ▸ | METAP2 | P50579 | 1/20 | 0.55 |
| ▸ | METAP1 | P53582 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | AGER | Q15109 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1267244 | 0.82 | NPC1 (0.71) | NPC1RAB9ASCDSMN1; SMN2LMNA | |
| SCHEMBL995829 | 0.82 | NPC1 (1.00) | NPC1RAB9ASCDSMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL27594584 | 0.80 | NPC1 (0.97) | NPC1RAB9ASCDSMN1; SMN2LMNA | |
| SCHEMBL8127812 | 0.77 | AQP4 (0.60) | RAB9ASMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL16562033 | 0.77 | SCD (1.00) | NPC1RAB9ASCDSMN1; SMN2LMNA | |
| SCHEMBL3178619 | 0.77 | NPC1 (0.72) | NPC1RAB9ASCDSMN1; SMN2LMNA | |
| SCHEMBL27739695 | 0.75 | NPC1 (0.70) | NPC1RAB9ASCDSMN1; SMN2LMNA | |
| SCHEMBL4285954 | 0.75 | NPC1 (0.85) | NPC1RAB9ASCDSMN1; SMN2LMNA | |
| SCHEMBL2628996 | 0.75 | NPC1 (0.76) | NPC1RAB9ASCDSMN1; SMN2LMNA | |
| SCHEMBL8125122 | 0.75 | SMN1; SMN2 (0.60) | NPC1RAB9ASMN1; SMN2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100430386-C | Phenylalanine derivatives as depeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO INC (US) | 2008-11-05 | — | — | CN | claimed |
| EP-1562925-B1 | PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2007-01-03 | — | — | EP | claimed |
| US-7157490-B2 | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-01-02 | — | — | US | claimed |
| CN-1735605-A | Phenylalanine derivative is used for the treatment of or prevent diabetes as depeptidyl peptidase inhibitors | MERCK & CO INC (US) | 2006-02-15 | — | — | CN | claimed |
| US-20050222140-A1 | Phenylalanine derivatives as depeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2005-10-06 | — | — | US | claimed |
| EP-1562925-A1 | PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| WO-2004043940-A1 | PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-05-27 | — | — | WO | claimed |
| EP-0830349-B1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | DU PONT PHARM CO (US) | 2000-03-22 | — | — | EP | claimed |
| EP-0830349-A1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-25 | — | — | EP | claimed |
| WO-1996039393-A1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-12 | — | — | WO | claimed |
| CN-100430386-C | Phenylalanine derivatives as depeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO INC (US) | 2008-11-05 | — | — | CN | disclosed |
| EP-1562925-B1 | PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2007-01-03 | — | — | EP | disclosed |
| US-7157490-B2 | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-01-02 | — | — | US | disclosed |
| CN-1735605-A | Phenylalanine derivative is used for the treatment of or prevent diabetes as depeptidyl peptidase inhibitors | MERCK & CO INC (US) | 2006-02-15 | — | — | CN | disclosed |
| US-20050222140-A1 | Phenylalanine derivatives as depeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2005-10-06 | — | — | US | disclosed |
| EP-1562925-A1 | PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004043940-A1 | PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| EP-0830349-B1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | DU PONT PHARM CO (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-1996039393-A1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-12 | — | — | WO | disclosed |
| US-5532356-A | Method for preparing N,N'-disubstituted cyclic ureas | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222140-A1 | Phenylalanine derivatives as depeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | NPC1 1410/4885RAB9A 4416/4885SCD 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.